Take a look at our previous reports:

Half-year financial report 2023

Contingencies and commitments

Contractual obligations and commitments

We have certain purchase commitments principally with CRO subcontractors and certain collaboration partners.

On 30 June 2023, we had outstanding obligations for purchase commitments, which become due as follows:

(thousands of €)

Total

Less than
1 year

1 – 3 years

3 – 5 years

More than
5 years

Purchase commitments

404,939

232,405

134,978

35,629

1,926

In addition to the table above, we have a contractual cost sharing obligation related to our collaboration agreement with Gilead for filgotinib. The contractual cost sharing commitment amounted to €174.4 million at 30 June 2023 for which we have direct purchase commitments of €100.9 million at 30 June 2023 reflected in the table above.

Contingent liabilities and assets

We refer to our Annual Report 2022 for a description of our contingent liabilities and assets.

Contract research organization (CRO)
Organization which provides drug discovery and development services to the pharmaceutical, biotechnology and medical devices industry
Filgotinib
Formerly known as GLPG0634, commercial name is Jyseleca®. Small molecule preferential JAK1 inhibitor, approved in RA and UC in the European Union, Great-Britain and Japan. Phase 4 studies in both RA and UC, and a Phase 3 study in AxSpA are ongoing